{
    "nctId": "NCT06076772",
    "briefTitle": "Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients",
    "officialTitle": "Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "Investigator will evaluate the patients and treatment characters in counts and percentage of developing high-grade neutropenia induced by palbociclib.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological pathological confirmation of primary breast cancer or metastatic disease.\n* Hormonal receptor-positive, HER2 negative.\n* Metastatic breast cancer at presentation (Den novo) or recurrent.\n* Patients did not receive any previous systemic therapy for metastatic disease.\n* Performance status (ECOG) 0-2.\n\nExclusion Criteria:\n\n* Patient with co-morbidity\n* Pregnant and breast lactating women",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}